Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγrIIIa gene

Blood

Volumn 99, Issue 3, 2002, Pages 754-758

  Cartron, Guillaume ^a,b   Dacheux, Laurent ^a,b   Salles, Gilles ^a,b   Solal Celigny, Philippe ^a,b   Bardos, Pierre ^a,b   Colombat, Philippe ^a,b   Watier, Hervé ^a,b  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G1; RITUXIMAB;

ADULT; ALLOTYPE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE LOCATION; GENE REARRANGEMENT; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PHARMACOGENETICS; PRIORITY JOURNAL;

EID: 0036464719     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.3.754     Document Type: Article

References (36)

1. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal anti-body (IDEC-C2B8) in patients with recurrent B-cell lymphoma
2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
3. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
4. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
5. Rituximab (anti-CD20 monoclonal antibody) as first-line therapy of follicular lymphoma patients with low tumor burden: Clinical and molecular evaluation
6. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
7. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
8. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
9. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate or high-grade non-Hodgkin's lymphoma (NHL)
10. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
11. Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms
12. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
13. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
14. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
15. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
16. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
17. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2
18. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas
19. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
20. The role of Fcγ receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals
21. Fcγ receptor polymorphisms in Wegener's granulomatosis: Risk factors for disease relapse
22. Immunoglobulin G Fc-receptor (FcγR) IIA and IIIB polymorphisms related to disability in MS
23. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype
24. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease
25. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc γRIII complex
26. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
27. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires
28. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
29. Rapid detection of the Fc γ RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED)
30. Nonparametric estimation from incomplete observations
31. A triallelic Fc γ receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc γ RIIIa
32. Human Fc γ RIII: Cloning, expression, and identification of the chromosomal locus of two Fc receptors for IgG
33. Linkage disequilibria between Duffy blood groups, Fc γ IIa and Fc γ IIIb allotypes
34. High resolution mapping of the binding site on human IgG1 for Fc γ RI, Fc γ RII, Fc γ RIII, and FcRn and design of IgG1 variants with improved binding to the Fc γ R
35. A novel PCR-based method for direct Fcγ receptor IIIa (CD16) allotyping
36. Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations